Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.58 |
| ▸ | F10 | P00742 | 1/20 | 0.54 |
| ▸ | BCHE | P06276 | 2/20 | 0.53 |
| ▸ | PTPRC | P08575 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1548932 | 0.90 | F10 (0.62) | MAOBF10BCHEPTPRCPTPN1 | |
| SCHEMBL12585463 | 0.90 | GSTP1 (0.54) | MAOBPTPRCPTPN1LMNACYP1A2 | |
| SCHEMBL29411728 | 0.89 | MAOB (0.68) | MAOBBCHELCKCYP4F2CYP4A11 | |
| SCHEMBL80829 | 0.89 | MAOB (0.68) | MAOBBCHELCKCYP4F2CYP4A11 | |
| SCHEMBL28798163 | 0.85 | CYP4F2 (0.56) | MAOBF10BCHEPTPRCPTPN1 | |
| SCHEMBL21429714 | 0.82 | MAOB (0.55) | MAOBBCHECYP4F2CYP4A11LMNA | |
| SCHEMBL15309991 | 0.82 | MAOB (0.50) | MAOBPTPRCPTPN1F2SMN1; SMN2 | |
| SCHEMBL31139262 | 0.82 | TSHR (0.57) | MAOBBCHECYP4F2CYP4A11FFAR1 | |
| SCHEMBL9707070 | 0.82 | FFAR1 (0.59) | MAOBBCHELCKCYP4F2CYP4A11 | |
| SCHEMBL15761340 | 0.82 | BCHE (0.70) | MAOBF10BCHELCKCYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2499112-B1 | SUBSTITUTED 3-(PHENOXYMETHYL) BENZYL AMINES AND PERSONAL CARE COMPOSITIONS | UNILEVER PLC NO 41424 (GB) | 2013-10-16 | — | — | EP | disclosed |
| US-8425885-B2 | Substituted 3-(phenoxymethyl) benzyl amines and personal care compositions | CONOPCO, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8425885-B2 | Substituted 3-(phenoxymethyl) benzyl amines and personal care compositions | CONOPCO, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2499112-A1 | SUBSTITUTED 3-(PHENOXYMETHYL) BENZYL AMINES AND PERSONAL CARE COMPOSITIONS | Unilever Plc, A Company Registered In England And Wales under company no. 41424 of Unilever House (GB) | 2012-09-19 | — | — | EP | disclosed |
| US-20110110871-A1 | SUBSTITUTED 3-(PHENOXYMETHYL) BENZYL AMINES AND PERSONAL CARE COMPOSITIONS | CONOPCO, INC., D/B/A UNILEVER (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110110871-A1 | SUBSTITUTED 3-(PHENOXYMETHYL) BENZYL AMINES AND PERSONAL CARE COMPOSITIONS | CONOPCO, INC., D/B/A UNILEVER (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110110871-A1 | SUBSTITUTED 3-(PHENOXYMETHYL) BENZYL AMINES AND PERSONAL CARE COMPOSITIONS | CONOPCO, INC., D/B/A UNILEVER (US) | 2011-05-12 | — | — | US | disclosed |
| WO-2011054805-A1 | SUBSTITUTED 3-(PHENOXYMETHYL) BENZYL AMINES AND PERSONAL CARE COMPOSITIONS | UNILEVER PLC (GB) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110110871-A1 | SUBSTITUTED 3-(PHENOXYMETHYL) BENZYL AMINES AND PERSONAL CARE COMPOSITIONS | TYR, CUTA, BRD3 | MAOB 300/4885F10 1436/4885BCHE 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.